Cerenovus, part of DePuy Synthes Products, Inc.
Clinical trials sponsored by Cerenovus, part of DePuy Synthes Products, Inc., explained in plain language.
Medical device company focused on neurovascular care, owned by Johnson & Johnson.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Brain artery block shows promise for stopping migraines Results expected Dec 2026 (estimated)
-
Glue embolization may cut repeat brain bleed surgery
Disease control CompletedThis study tested whether adding a glue-like embolization to standard care reduces the chance of a chronic subdural hematoma coming back or needing another surgery. 376 adults with this type of brain bleed were randomly assigned to standard care alone or standard care plus the em…
Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Brain aneurysm coils put to the test in largest Real-World study
Disease control CompletedThis study tracked 723 people with brain aneurysms treated using MICRUSFRAME and GALAXY coils, sometimes with a PulseRider device. The goal was to see how well the coils blocked the aneurysm and kept it closed after 12 months. Researchers collected data from real hospital setting…
Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC